Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Artavazd Arumov

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Blood Cancer Journal|February 8, 2024
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomasAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2019
T Cell-Activating Bispecific Antibodies in Cancer TherapyAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Trends in Biotechnology|April 9, 2021
Potency Meets Precision in Nano-optimized ChemotherapeuticsArtavazd Arumov, Asaad Trabolsi, Jonathan H Schatz
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 2, 2025
Bispecific Antibodies in Hematologic Malignancies: Attacking the FrontlineToral Shastri, Asaad Trabolsi, Artavazd Arumov, et al.
Cancers|May 13, 2026
Transferrin Receptor Overexpression in Solid Tumors Is Associated with Inflamed Microenvironments and Upregulated Immune Checkpoints, with Implications for Immunotherapy SensitivityAsaad Trabolsi, Marianna Lekakis, Peter M Commisso, et al.
Cell Reports|October 13, 2021
Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatomeJ J David Ho, Tyler A Cunningham, Paola Manara, et al.
Cancer Research|November 12, 2020
Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin ReceptorsArtavazd Arumov, Piumi Y Liyanage, Asaad Trabolsi, et al.
Oncogene|December 6, 2019
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphomaSoumya S Rajan, Amit Dipak Amin, Lingxiao Li, et al.
Breast Cancer Research and Treatment|August 20, 2022
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility studyElaine M Walsh, Ayca Gucalp, Sujata Patil, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
The cyclin-G associated kinase (GAK) is a novel mitotic kinase and therapeutic target in diffuse large B-cell lymphomaOlivia B Lightfuss, Preet Kumar, Lingxiao Li, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Blood Cancer Journal|February 8, 2024
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomasAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2019
T Cell-Activating Bispecific Antibodies in Cancer TherapyAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Trends in Biotechnology|April 9, 2021
Potency Meets Precision in Nano-optimized ChemotherapeuticsArtavazd Arumov, Asaad Trabolsi, Jonathan H Schatz
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 2, 2025
Bispecific Antibodies in Hematologic Malignancies: Attacking the FrontlineToral Shastri, Asaad Trabolsi, Artavazd Arumov, et al.
Cancers|May 13, 2026
Transferrin Receptor Overexpression in Solid Tumors Is Associated with Inflamed Microenvironments and Upregulated Immune Checkpoints, with Implications for Immunotherapy SensitivityAsaad Trabolsi, Marianna Lekakis, Peter M Commisso, et al.
Cell Reports|October 13, 2021
Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatomeJ J David Ho, Tyler A Cunningham, Paola Manara, et al.
Cancer Research|November 12, 2020
Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin ReceptorsArtavazd Arumov, Piumi Y Liyanage, Asaad Trabolsi, et al.
Oncogene|December 6, 2019
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphomaSoumya S Rajan, Amit Dipak Amin, Lingxiao Li, et al.
Breast Cancer Research and Treatment|August 20, 2022
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility studyElaine M Walsh, Ayca Gucalp, Sujata Patil, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
The cyclin-G associated kinase (GAK) is a novel mitotic kinase and therapeutic target in diffuse large B-cell lymphomaOlivia B Lightfuss, Preet Kumar, Lingxiao Li, et al.
Pageof 1